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Abstract
Background: A demyelinating polyneuropathy with focally folded myelin sheaths was
reported in 3 Miniature Schnauzers in France in 2008 and was predicted to represent
a naturally occurring canine homologue of Charcot-Marie-Tooth (CMT) disease. A
genetic variant of MTRM13/SBF2 has been identified as causative in affected Minia-
ture Schnauzers with this polyneuropathy.
Objective: To provide data on the long-term progression in affected Miniature
Schnauzers from Spain confirmed with the MTRM13/SBF2 genetic variant.
Animals: Twelve Miniature Schnauzers presented between March 2013 and June
2019.
Methods: Only dogs presented with consistent clinical signs and homozygous for the
MTRM13/SBF2 genetic variant were included. Clinical signs, age of onset and presen-
tation, time from onset to presentation, treatment, outcome, and time from diagnosis
to final follow-up were retrospectively reviewed.
Results: The hallmark clinical signs at the time of presentation were regurgitation
with radiologically confirmed megaesophagus (11/12) and aphonic bark (11/12) with
or without obvious neuromuscular weakness despite electrodiagnostic evidence of
appendicular demyelinating polyneuropathy. Age of onset and clinical presentation
were 3-18 and 4-96 months, respectively. Treatment was mostly symptomatic and
consisted of head elevation during meals, antacids, prokinetics, bethanechol, sildena-
fil, mirtazapine, or some combination of these. During the follow-up period
(7-73 months), clinical signs were unchanged in (11/12) cases with aspiration pneu-
monia developing occasionally (6/12) and being the cause of death in 1 dog.
Conclusions and Clinical Importance: Demyelinating polyneuropathy of Miniature
Schnauzers tends to remain stable over the long term leading to a good prognosis
with preventive feeding measures and symptomatic treatment to control aspiration
pneumonia.
Abbreviations: CMAP, compound muscle action potential; CMT, Charcot-Marie-Tooth; CSF, cerebrospinal fluid; MTMR, myotubularin-related; NCV, nerve conduction velocities; SBF2, set-
binding factor 2; T4, thyroxine.
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1 | INTRODUCTION
Inherited peripheral neuropathies in dogs are a heterogeneous group
of degenerative diseases affecting motor or sensory or both and auto-
nomic peripheral nerves. More than 50 inherited neuropathies have
been reported in the veterinary literature, for which clinical, electro-
physiological, histopathological, and, for some, mode of inheritance
data are available.1 However, the mode of inheritance often can only
be speculated upon and the specific genetic variants rarely are identi-
fied.2,3 For many inherited peripheral neuropathies in human beings,
the known mutations have allowed further characterization of this
group of diseases.3 The available knowledge about hereditary neurop-
athies in humans may be useful to identify genetic mutations in
affected dogs and vice versa.1
A presumptive inherited autosomal recessive demyelinating poly-
neuropathy was reported in 3 young Miniature Schnauzers in France
in 2008.4 The affected dogs were presented for clinical signs of
laryngeal paralysis or megaesophagus. Although generalized weakness
was not clinically detected, electrodiagnostic testing identified a
marked decrease in motor and sensory nerve conduction velocities
(NCV), indicating involvement of clinically unaffected nerves.
Megaesophagus was present in all of the affected French dogs, and
the electrophysiological findings were suggestive of a predominantly
demyelinating disease. Variable thickness of the myelin sheath with
areas of segmental demyelination and multifocal areas of focally
folded myelin sheaths, also known as tomacula, were found in periph-
eral nerve biopsy specimens.4 This disease was predicted to represent
a naturally occurring canine form of Charcot-Marie-Tooth (CMT) disease
(specifically CMT1, B1, and 4B2). In veterinary medicine, other neuropa-
thies in dogs such as hypertrophic neuropathy in the Tibetan Mastiff,
with characteristic onion bulb formation,5,6 and hypomyelinating neurop-
athy in the Golden Retriever7 have been thought to share similarities
with specific forms of CMT disease. Additionally, a suspected inherited
tomaculous neuropathy has been described in cattle8 and a neuropathy
has been described in chickens associated with acquired riboflavin
deficiency.9
Different genes and variants have been implicated in the path-
ogenesis of hereditary forms of demyelinating neuropathies in
humans associated with focally folded myelin sheaths.10 The pro-
tein products of these mutated genes include the myelin compo-
nents PMP22, P0, periaxin, proteins regulating myelin gene
transcription early growth response 2 and intracellular Schwann
cell proteins involved in the synthesis, transport and degradation of
myelin proteins, including the myotubularin-related (MTMR) pro-
teins.4 Although degenerative polyneuropathies in dog breeds were
reviewed in 2011 and compared with CMT,1 none of them were
found to share the same mutation as a specific form of the human
disease. The MTMR13/SBF2 (set-binding factor 2) gene has now
been implicated in degenerative polyneuropathy in both human
beings and the dogs of this previous report.11
Our objective was to provide new clinical data on demyelinating
polyneuropathy associated with a genetic variant of the SBF gene
family and describe the long-term clinical progression in a larger group
of affected Miniature Schnauzers diagnosed in Spain. This new infor-
mation will increase awareness of the disease in the veterinary com-
munity, while providing new data on disease progression.
2 | MATERIALS AND METHODS
2.1 | Case selection
Between March 2013 and April 2014, Miniature Schnauzers with pre-
sumed autosomal recessive demyelinating polyneuropathy of Minia-
ture Schnauzers and with compatible clinical, electrodiagnostic, or
histopathologic findings or some combination of these were evaluated
at 4 Spanish veterinary hospitals. Genome-wide association screening
using DNA from 10 affected dogs (2 original French cases,4 7 Spanish
cases, and 1 Belgian case) and 5 nonaffected siblings identified a vari-
ant in intron 19 of the SBF2 gene11 in all affected dogs, and heterozy-
gosity for the mutation in 3/5 of the nonaffected siblings.
Comprehensive details of the mutation detection process have been
described in a separate study11 and included a genome-wide associa-
tion study (GWAS) and resequencing of candidate genes.
After gene discovery, additional Spanish dogs evaluated between
June 2014 and June 2019 with consistent clinical signs were identi-
fied to be homozygous for the SBF2 genetic variant, and subsequently
also were included in our report.
We describe the presenting clinical signs, age of onset, age at pre-
sentation, time from onset to presentation, treatment, outcome, and
time from diagnosis to final outcome. Follow-up information was col-
lected during routine reevaluations or telephone interviews with the
owners. Where available, blood results, cerebrospinal fluid (CSF) anal-
ysis, electrodiagnostic testing, and histopathologic findings also were
included.
2.2 | Electrodiagnostic studies
A Keypoint portable electrodiagnostic unit (Alpine Biomed, Denmark)
was used for electromyography (EMG) and motor NCV testing. Elec-
tromyography and motor NCV testing were performed under general
anesthesia using IM concentric (coaxial) needles as recording elec-
trodes for the EMG and monopolar needles for the motor NCV.
Appendicular, axial, cranial, and laryngeal muscles were evaluated by
EMG. Motor NCV were recorded for the tibial and ulnar nerves. The F
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waves and amplitude of compound muscle action potentials (CMAP)
after repetitive stimulation also were determined. Reference values
were 46 ± 7 m/s for conduction velocities of tibial and ulnar nerves12
and 12.8 ± 3.9 to 16.2 ± 4.3 mV and 13.6 ± 4 to 20.2 ± 5.3 mV for
the CMAP amplitudes of the ulnar and tibial nerves, respectively.13
A nonaffected sibling was used as a matched control.
2.3 | Histopathology and histochemistry of muscle
and peripheral nerve biopsy specimens
Muscle and nerve biopsy specimens from the cranial tibial muscle and
common peroneal nerve, respectively, were collected under general
anesthesia after electrodiagnostic testing. Immediately after collec-
tion, unfixed chilled muscle and formalin-fixed muscle were shipped
by a courier service to the Comparative Neuromuscular Laboratory,
University of California, San Diego. Upon receipt, unfixed muscle was
snap frozen in isopentane precooled in liquid nitrogen and stored at
−80!C until further processed. Formalin-fixed muscle was processed
by standard methods into paraffin. Light microscopic evaluation of
histological and histochemical stains and reactions was performed
according to standard protocols14 and included hematoxylin and
eosin, modified Gomori trichrome, periodic acid Schiff, phosphorylase,
esterase, myofibrillar ATPase reactions with preincubation pH of 9.8
and 4.3, reduced nicotinamide adenine dinucleotide-tetrazolium
reductase, succinic dehydrogenase, acid and alkaline phosphatase, and
oil red O.
Specimens from the peroneal nerve were immersion fixed in 10%
buffered formalin before shipment to the Comparative Neuromuscu-
lar Laboratory. Upon receipt, nerves were postfixed in 1% aqueous
osmium tetroxide for 3 hours and then dehydrated in a graded alcohol
series and propylene oxide. After infiltration with a 1:1 mixture of pro-
pylene oxide and araldite resin for 4 hours, nerves were placed in
100% araldite resin overnight and then embedded in fresh araldite
resin. Thick sections (1 μm) were cut and stained with para-
phenylediamine before light microscopic evaluation.
3 | RESULTS
3.1 | Clinical presentation, clinical pathology
results, and additional testing
Twelve Miniature Schnauzers (5 intact males, 4 intact females,
1 neutered male, and 2 neutered females) were included. Median age
of onset was 12 months (range, 3-18 months) and median age at pre-
sentation was 25 months (range, 4-96 months). Median time from
onset of clinical signs to presentation was 11 months (range,
0-84 months). Regurgitation associated with megaesophagus and
aphonic bark were the most frequent clinical signs in 11/12 cases.
Other inconsistently present clinical signs were slightly delayed con-
scious postural reactions (6/12) and weak flexor reflex in the pelvic
limbs (3/12). One dog had muscle tremors in the pelvic limbs and
decreased palpebral reflex, and another dog had exercise intoler-
ance. One of the included dogs also presented with seizures,
decreased left menace response and delayed left-sided postural
reactions suggesting an independent right forebrain lesion. Com-
puted tomography of the brain with IV contrast medium and cister-
nal CSF analysis were performed and found to be normal. Thus,
epilepsy of unknown origin was suspected. These findings are sum-
marized in Supplemental Information.
Blood evaluations including CBC and serum biochemistry profile
(8/12), serum thyroxine and thyroid stimulating hormone concentra-
tion (3/12), adrenocorticotropic hormone stimulation test (3/12), and
dynamic bile acid stimulation test (1/12) were performed and results
were within reference ranges, except for 1 dog that had an increased
serum cholesterol concentration. Acetylcholine receptor antibody
titers were determined in 2/12 dogs and were within the reference
range. Echocardiography and a Holter evaluation in 2 of the dogs
were normal. In 2 additional dogs, lumbar CSF analysis was within the
reference range.
3.2 | Electrodiagnostic studies
Electrodiagnostic studies were performed in 5/12 dogs on the right
tibial (2/5), left tibial (4/5), right ulnar (1/5), and left ulnar (2/5) nerves.
The median motor NCV was 29.55 m/s (range, 23.2-35.9 m/s) in the
right tibial nerve and 26.8 m/s (range, 20-52.2 m/s) in the left tibial
nerve. The motor NCV in the sole right ulnar nerve tested was
24.4 m/s proximally and the motor NCV in the left ulnar nerves tested
were 36.7 m/s (1/2) and 18.2 m/s (1/2), both proximally. The CMAP
amplitude was measured in 2 right tibial nerves and found to be
4.4 mV proximally and 4.6 mV distally, and 6.1 mV proximally and
3.4 mV distally, respectively; in 3 left tibial nerves it was found to be
5.5 mV proximally and 6.4 mV distally, 4.2 mV proximally and
11.7 mV distally, and 11 mV proximally and 16.6 mV distally; and in
1 right ulnar it was found to be 9.0 mV proximally and 12.4 mV dis-
tally. The shape of the curve was polyphasic in 3/5. In the nonaffected
sibling used as an age-matched control, the right tibial and left ulnar
nerves were evaluated. Motor NCV was 55.9 m/s proximally and
71.4 m/s distally for the right tibial nerve, and 55.7 m/s for the left
ulnar nerve. The CMAP amplitude was 18.2 mV proximally and
24.1 mV distally for the right tibial nerve and 17.7 mV proximally and
17.1 mV distally for the left ulnar nerve.
In summary, the most prominent abnormalities were slow motor
NCV (range, 20-42 m/s) and low CMAP amplitudes (range,
4.2-46.0 mV) associated with polyphasic CMAPs (Supplemental Infor-
mation). These electrophysiological findings were suggestive of a
demyelinating disease of the peripheral nerves tested (Figure 1).
3.3 | Histopathology and histochemistry
Muscle and peripheral nerve biopsy specimens were obtained in
1 affected Miniature Schnauzer dog. No specific abnormalities were
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identified in the biopsy specimens from the cranial tibial muscle. The
density of myelinated nerve fibers was subjectively appropriate in the
peroneal nerve. Numerous inappropriately thin myelinated fibers and
scattered hypermyelinated fibers consistent with tomacula were
observed (Figure 2). These findings were consistent with those
described in the previous report.4
3.4 | Genetic testing
All of the included cases were tested for the same splicing mutation in
intron 19 of the MTMR13/SBF211 gene and found to be homozygous
for the mutation. In a litter of 5 2-month-old dogs, 2 of the litter were
found to be carriers (heterozygous for the mutation) and the other
3 had 2 normal copies of the gene.
3.5 | Treatment and outcome
Treatment was aimed at ameliorating clinical signs and consisted of
head elevation during and 30 minutes after meals (12/12), as well as
F IGURE 1 Motor nerve conduction velocities (NCV) of the right tibial nerve of a nonaffected dog (A) and affected dog (B) of the same litter.
Note the slow motor NCV (range, 20-42 m/s) and polyphasic and low compound muscle action potential (CMAP) amplitudes in the affected dog
in contrast with the nonaffected dog
F IGURE 2 Biopsy specimen from the peroneal nerve (1-μm-thick
resin sections). Characteristic changes include nonconcentric myelin
protrusions around nerve fibers consistent with tomacula (arrows
with short tails) and inappropriately thin myelinated fibers (arrows
with long tails). Axonal degeneration was not a feature
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antacids (omeprazole [3/12] and famotidine [1/12]), intestinal protec-
tants (sucralfate [2/12] and amalgate [1/12]), prokinetics (met-
oclopramide [3/12], cinitapride [1/12] and mirtazapine [3/12]), and
antiemetics (maropitant [2/12]). In 3 cases, sildenafil was used as
adjunctive treatment. Bethanechol also was used in 2/12 cases. The
frequency of regurgitation remained unchanged in all dogs except in
2 of those receiving mirtazapine, in which episodes decreased from
several times daily to once every 2 to 3 days. In the dog with seizures,
phenobarbitone was added to the treatment regimen. When aspira-
tion pneumonia developed (6/12), antibiotics also were prescribed
(amoxicillin-clavulanate acid, 4/12; enrofloxacin, 1/12; and cephalexin,
1/12).
Median time from diagnosis to final follow-up was 22.5 months
(range, 7-73 months). Regardless of treatment, clinical signs slowly
progressed in 1/12 dogs leading to clinically evident pelvic limb weak-
ness, muscular atrophy, decreased flexor reflexes, and delayed pos-
tural reactions 67 months after diagnosis. In the other dogs, clinical
signs were unchanged for 0 to 88 months with aspiration pneumonia
developing occasionally in 6 dogs. Four dogs were dead at the time of
writing. Death was directly attributed to the disease in only 1 dog
after developing aspiration pneumonia 73 months after diagnosis.
One dog was euthanatized because of acute renal failure caused by
Leishmania spp. infection 36 months after diagnosis. Another dog died
after a short period of anorexia 17 months after diagnosis, and the
cause of death in the last dog 26 months after diagnosis was
unknown.
4 | DISCUSSION
Charcot-Marie-Tooth disease constitutes a large group of hereditary
motor and sensory peripheral neuropathies in humans characterized
by phenotypic and genetic heterogeneity, which can be inherited as
autosomal dominant, autosomal recessive or X-linked traints. Clinical,
electrophysiological and pathological features allow differentiation of
3 main subtypes: demyelinating (CMT1), axonal (CMT2), and interme-
diate (I-CMT) forms.15 To date, genetic variants in >24 genes have
been found to cause different forms of CMT disease in people.10
Inherited motor and sensory neuropathies in 22 dog breeds have been
reviewed and suggested to have a link with CMT subtypes in humans.
However, in contrast with CMT, all of the described inherited
polyneuropathies in dogs seem to share an autosomal recessive mode
of inheritance, although not confirmed by pedigree analysis. It is also
difficult to clearly differentiate between demyelinating and axonal
neuropathies, and onion bulb formation is infrequent in dogs.1
In humans, mutations in the SBF2 gene causes CMT4B2. The
SBF2 gene encodes for a pseudophosphatase of the MTMR protein
family, which has a role in regulating vesicular trafficking in Schwann
cells. Loss of this protein may lead to uncontrolled folding of myelin,
producing the typical focally folded myelin sheaths or tomacula seen
in CMT4B15 and in affected Miniature Schnauzer dogs. Despite dogs
and humans sharing a mutation in the same gene (SBF2) and having a
similar histopathologic appearance of the nerves, the clinical
phenotype differs substantially between the human and the canine
forms. Regurgitation and aphonic bark because of megaesophagus
and laryngeal paralysis predominate in dogs, and pelvic limb weakness
is rare. On the other hand, appendicular limb weakness and decreased
reflexes dominate the human phenotype. In human medicine, it is well
known that different genetic variants in the same gene can give rise
to markedly different phenotypes.16 Indeed, involvement of bulbar
and facial nerves resulting in vocal cord paresis or diaphragm weak-
ness most frequently has been reported in the CMT4B1 form (caused
by a mutation in the MTMR2 gene) or other CMT types, but not in
CMT4B2.15-18 In 1 report of a patient with CMT disease, esophageal
and gastric smooth muscle function impairments were observed, but
this clinical scenario is not usually described.19 Substantial divergence
in clinical signs between affected humans and dogs may be related to
the striated muscle of the esophagus in dogs as compared to smooth
muscle in humans. Theoretically, CMT disease in dogs may be domi-
nated by striated muscle dysfunction.19
The CMT4B2 disease is characterized by autosomal recessive
inheritance mode and often affects children between 4 and 13 years
of age (mean age, 8 years).15 This observation is comparable to the
findings in the affected Miniature Schnauzers with a young age of
onset (between 3 and 18 months of age). Electrodiagnostic findings
are characterized by a marked decrease in NCV and amplitude, and
prolonged distal latency. Although not evaluated in the Miniature
Schnauzer dogs, sensory NCV also are severely decreased. Fibrillation
potentials, positive sharp waves and a decrease in the recruitment
pattern of motor unit potentials are found in people during needle
electromyography. Polyphasic motor unit potentials and giant action
potentials can be present in distal muscles.15 In the dogs reported
here, slow motor NCV (range, 20-42 m/s), as well as polyphasic and
low CMAP amplitudes were found. In people, increased protein con-
centration (up to 280 mg/dL) may be found in lumbar CSF, despite
normal cell counts.15,20 Unfortunately, CSF was only evaluated in
3 dogs and results were within reference ranges.
Histopathological findings in CMT4B2 are characterized by a
severe loss of myelinated nerve fibers with the remaining fibers gen-
erally hypomyelinated, hypermyelinated or unmyelinated. The patho-
logical hallmark is the presence of nerve fibers with focal regions
where myelin is thrown into irregular protrusions from the outer mye-
lin sheath, known as myelin outfoldings or tomacula. Inward protru-
sions, which extend towards the axon, also are present and referred
to as myelin infoldings. The protrusion may contain axons or exclu-
sively Schwann cell cytoplasm. Supernumerary Schwann cell pro-
cesses or basal lamina structures may encircle some fibers (so-called
onion bulbs) indicating the occurrence of repeated episodes of demy-
elination and remyelination, and abnormal proliferation.21-23 Muscle
biopsy has been performed in a few patients and has identified only
minor abnormalities compatible with neurogenic atrophy.15,17 In the
sole dog in our series in which muscle and nerve biopsies were per-
formed, and in the French dogs previously reported,4 minimal to no
changes were identified in muscle biopsy specimens and inappropri-
ately thin myelinated nerve fibers and scattered hypermyelinated
fibers (tomacula) were identified.
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In human medicine, the diagnosis of CMT4 subtypes is based on
clinical findings, neurophysiologic studies, family history, and molecu-
lar genetic testing that ultimately permit the diagnosis.24 Treatment is
symptomatic and includes special shoes or ankle or foot orthoses or
both to correct foot drop and aid walking; surgery as needed for
severe pes cavus; forearm crutches, canes, and wheelchairs as needed
for mobility; exercise as tolerated; and treatment of pain, depression,
sleep apnea, and restless leg syndrome.24 In cases of vocal cord paral-
ysis, treatment may include cordotomy, vocal fold lateralization or
medialization to preserve speech, and tracheotomy.19 One patient
described with CMT syndrome and gastrointestinal involvement was
treated with promethazine, metoclopramide, and ondansetron, which
helped partially.25 In the dogs reported here, treatment was mostly
symptomatic and consisted of head elevation during meals, antacids,
prokinetics, and bethanechol resulting in little improvement in the fre-
quency of regurgitation. Sildenafil has been shown to decrease regur-
gitation frequency and increase weight gain in dogs with idiopathic
megaesophagus26 but was used in only 3 of our cases and resulted in
no short-term improvement, although owners withdrew the medica-
tion in 2 dogs less than a month after initiation. On the other hand,
bethanechol has been shown to increase the amplitude of esophageal
contractions.27 The lack of any clinically relevant improvement in our
cases and those reported in the literature could be a result of different
etiology of the megaesophagus in the dogs treated with bethanechol
or sildenafil. Also, metoclopramide and cisapride have been shown to
be ineffective and can even aggravate clinical signs.28,29 The antide-
pressant mirtazapine was used in 3 cases, resulting in a slight decrease
in the frequency of regurgitation in 2 of them, but the low number of
dogs receiving this medication precludes any conclusion on its effi-
cacy. The use of different treatments in our retrospective study, in
addition to the low number of cases, represent the major limitations
of our study. Additional studies are needed to evaluate the efficacy of
individual treatments in miniature Schnauzers with this demyelinating
polyneuropathy. Novel treatments such as ascorbic acid,30-33 proges-
terone antagonists (onapristone34 and lonaprisan35), curcumin36,37
and pharmacological inhibition of histone deacetylase 638 are being
studied in human medicine,39 but although >80 CMT-causing genes
have been identified to date, an effective treatment has not yet been
developed for these diseases in people.40
Animal models (primarily in mice and Drosophila spp.) representing
the most frequent forms of CMT in humans are now available,40,41 but
none is a spontaneously occurring disease. The disease described here is
the first spontaneously and naturally occurring demyelinating inherited
CMT polyneuropathy in a large animal model with a confirmed genetic
variation. However, the differences in phenotype compared to humans
might pose a limitation to the use of affected Schnauzers as an animal
model for the human disease. However, identification of a treatment
that slows progression of the disease in affected dogs still could be valu-
able for testing in a clinical trial of affected humans.
In CMT disease, life expectancy is not known to be altered in
most cases, with some patients presenting in infancy or early child-
hood with inability to ambulate and weakness of proximal and distal
muscles. In some cases, however, the neuropathy can lead to
restrictive pulmonary impairment, vocal cord dysfunction or sleep
disturbances,19 shortening lifespan, with death occurring in the fourth
or fifth decade, mostly as a result of respiratory failure.31 In the cases
described here, despite lack of an effective treatment, clinical signs
remained unchanged in all but 1 dog for up to 73 months, with aspi-
ration pneumonia developing occasionally (6/12). Only1 dog prog-
ressed slowly to clinically evident pelvic limb weakness 67 months
after diagnosis, but without impairment in quality of life. Although
4 dogs were dead at the time of writing, only 1 death was directly
attributed to the disease after development of aspiration pneumonia.
This finding demonstrates that the demyelinating polyneuropathy of
Miniature Schnauzers tends to remain stable, leading to a fair to
good prognosis if aspiration pneumonia and anorexia can be avoided
or managed.
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